Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
about
Interventions for treating intrahepatic cholestasis in people with sickle cell diseaseMagnesium for treating sickle cell diseaseInfection-related hemolysis and susceptibility to Gram-negative bacterial co-infectionMolecular pathophysiology of priapism: emerging targetsMagnesium for treating sickle cell diseasePulmonary complications of sickle cell disease.Platelets in pulmonary vascular physiology and pathology.Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.Heme degradation and vascular injury.A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis.Carbon monoxide promotes respiratory hemoproteins iron reduction using peroxides as electron donors.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsVasculopathy and pulmonary hypertension in sickle cell disease.Gas what: NO is not the only answer to sexual function.Pleiotropic effects of intravascular haemolysis on vascular homeostasis.Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertensionInorganic nitrite therapy: historical perspective and future directions.Priapism in sickle-cell disease: a hematologist's perspective.Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease MiceSickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia.Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation.Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.Translating NO biology into clinical advances: still searching for the right dictionary?Investigational drugs in sickle cell anemia.Sickle cell disease at the dawn of the molecular era.Sickle-cell disease and the heart: review of the current literature.A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease.Interventions for treating intrahepatic cholestasis in people with sickle cell disease.Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell MicePathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana
P2860
Q24187279-7110EC62-93D8-48A6-A493-D1F27011CBBAQ24193246-8A02D2E2-69F6-417B-905B-69CD6DF891F6Q26801651-7CD0F26B-DDBE-45CB-BA80-AFF3B4F85526Q27010069-32E058BA-A4C9-46C9-87BE-6A1DA0E4C883Q29994630-9F03A064-D789-4244-AF82-7B7C4CFC7C0BQ30515769-99C6505E-D070-4937-B92F-10CDBE1AE434Q33404240-4D1CB0B3-A46A-4915-9B7B-7B069817C55AQ33572814-73AECC8F-28B3-49D5-838A-2BA60F60C97CQ33649898-02FCD197-B361-4FA5-AC50-5BF889BB5781Q34038874-4683942D-7357-4FAD-9F69-38C5956FBEDCQ34200360-25445AA0-A93B-4F44-A0D6-82C050B98130Q34992760-30B576F1-A85F-4B27-B33A-729BD8808AB3Q35086394-DA69A314-D1DA-4595-A659-E75308F68674Q35204833-234BEEC7-1583-45E1-8390-DE6F453CD87DQ35535204-880CD0C1-15ED-4B40-B3FF-37214D75E5EBQ35540342-A6D04532-6029-4823-BBA1-D7A87592EE59Q35552149-EF43CFEC-7348-4F98-817C-85CD7B6EB297Q35658625-736ED35D-BC48-4ED1-9B98-C500411B32D2Q35737367-1A1F8455-747C-4349-9189-167ED3047C33Q36056143-3FB59177-DC87-4702-AFDD-1CDDAF109326Q36657988-BCB2E4B5-A367-40B0-B2C0-B21E642E18FDQ36697677-1293330C-D488-4645-AA3A-0542EF1B4416Q37307997-559C5C3E-6B78-40E3-89D2-2EBE34242BF4Q37398351-10FE0237-8106-499D-9915-F6E901D9C273Q37485631-3B2B3BD1-2C16-4B79-B1A6-7E48FADBD93CQ37603352-26A383A8-36B3-477F-BB40-4B0AD108CB80Q37650483-F95270AA-6300-4552-A31A-EBE831AF55B1Q38005233-E036B2E7-0565-4F20-A0FE-D74B97EA46ABQ38625485-9308CE4D-5493-4CD9-9C1D-3E87C70B46D9Q38651517-F245A194-CEA7-4ECF-8DC4-3346EF27F90AQ41151610-AB8840B7-D146-4FF6-BA91-5749E4BDFBABQ47799282-D14EDD13-DDEB-4375-ABF6-3A38FFE9E17DQ58761537-A982E563-6081-4AE4-822D-04A7549C261E
P2860
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@ast
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@en
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@nl
type
label
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@ast
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@en
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@nl
prefLabel
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@ast
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@en
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@nl
P2860
P356
P1476
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
@en
P2860
P304
P356
10.1001/JAMA.2008.598
P407
P577
2008-12-01T00:00:00Z